Prostate cancer is the most common cancer in Australia, with about 26,000 men diagnosed per year. The majority (more than 85% ...

Kairos Pharma Ltd (NYSE:KAPA) saw its stock jump 165% following the announcement of encouraging safety results from its ongoing Phase 2 clinical trial of ENV-105 in patients battling metastatic ...

Fred Hutch Cancer Center is leading the newly launched Vanguard Study, a national study of a new type of blood test that screens for several different cancers called multi-cancer detection (MCD) tests ...

A Flinders University study shows that bowel cancer survivors face an elevated risk of developing multiple primary cancers ...

Most men who are treated for prostate cancer according to modern guidelines have good survival rates and the majority of ...

Most men who are treated for prostate cancer according to modern guidelines have good survival rates and the majority of these men will die of causes ...

A new type of medical treatment is scheduled to travel the highways and byways from headquarters in Temple in an effort to ...

Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.

Kenya’s fight against cancer has entered a new phase, driven by technological breakthroughs that promise to transform diagnosis, treatment, and survival rates.

During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic prostate cancer.

ArteraAI Prostate analyzes digital pathology images of a prostate cancer biopsy slide to help clinicians predict long-term outcomes.